Full Press Release Details
CAPITALIZATION AND INDEBTEDNESS
following table sets forth our cash and cash equivalents, short term debt, including current portion of long term debt and our capitalization as of December 31, 2015 (prepared on the basis of International Financial Reporting Standards as
issued by the International Accounting Standards Board ( IFRS )).
| Dec. 31, 2015 | ||||
| millions | ||||
| (A) Cash and cash equivalents | 9,148 | |||
| (B) Short-term debt, and current portion of long-term debt | 3,436 | |||
| (C) Long-term debt | 13,118 | |||
| (D) Equity attributable to non-controlling interests | 161 | |||
| (E) Equity attributable to equity holders of Sanofi: | ||||
| Share capital | 2,611 | |||
| Additional paid-in capital and retained earnings | 52,010 | |||
| Treasury shares | (298 | ) | ||
| Stock options and other share-based payments | 2,814 | |||
| Other items recognized directly in equity | 912 | |||
| Equity attributable to equity holders of Sanofi | 58,049 | |||
| (F) Capitalization (C+D+E) | 71,328 |
As of March 15, 2016, the total aggregate amount of U.S. commercial paper outstanding was US$1.5 billion. No
U.S. commercial paper was outstanding as of December 31, 2015.
As of March 10, 2016, following the repurchase and cancellation of
shares in accordance with its share repurchase program, the value of the treasury shares of Sanofi amounted to 1,706 million.